Anti-HER3 antibodies and uses of same
An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a K D value of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HER3 and NRG-induced cancer cell migration and proliferation. Additionally clones NG83 and NG140 are provided which bind human HER-3 with a K D value of 10 nM or lower.
1. An isolated antibody comprising an antigen recognition domain specifically binding human HER-3 with a K D value of 10 nM or lower, wherein said antigen recognition domain comprises complementarity determining region (CDR) amino acid sequences as set forth in SEQ ID NOs: 1 (CDR1), 2 (CDR2) and 3 (CDR3), being sequentially arranged from N to C on a light chain of said antibody; and 4 (CDR1), 5 (CDR2) and 6 (CDR3) being sequentially arranged from N to C on a heavy chain of said antibody) (Clone NG33), wherein said antibody inhibits neuregulin (NRG) binding to said human HER3 and NRG-induced cancer cell migration and proliferation.
2. The isolated antibody of claim 1 , wherein said antibody is attached to a heterologous moiety.
3. The isolated antibody of claim 2 , wherein said heterologous moiety is a pharmaceutical agent.
4. The isolated antibody of claim 3 , wherein said pharmaceutical agent comprises a cytotoxic agent.
5. A kit comprising the isolated antibody of claim 1 and instructions for using the isolated antibody to detect a HER3 polypeptide.
6. A kit comprising the isolated antibody of claim 1 and a pharmaceutical agent.
7. A method of determining presence of HER3 polypeptide in a cell suspected of containing the HER3 polypeptide, the method comprising contacting the cell with the isolated antibody of claim 1 under conditions which allow formation of an immunocomplex comprising the HER3 polypeptide and the isolated antibody, and determining presence of said immunocomplex, thereby determining presence of HER3 polypeptide in the cell.
8. A method of treating a HER3 associated cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the isolated antibody of claim 1 , thereby treating the HER3 associated cancer.
9. The method of claim 8 , further comprising analyzing expression of said HER3 and/or NRG in cells of said cancer.
10. The method of claim 8 wherein said cancer is selected from the group consisting of ovarian cancer, breast cancer, lung cancer, pancreatic cancer and gastric cancer.
11. The method of claim 8 , wherein said cancer is gastric cancer.